(Obstet Gynecol 2011;117:627-35)
DOI:10.1097/AOG.0b013e31820afaf2″
“Aim: To compare the feasibility, safety and outcome of IMPELLA Recover LP2.5 cardiac assistance and intra aortic balloon pump (IABP) in patients with post-cardiac arrest shock.
Background: The high early mortality rate of post-cardiac arrest patients is attributed to a “”post cardiac arrest syndrome”" characterized by an acute and transient left ventricular (LV) systolic dysfunction. LV assistance with IMPELLA selleck chemical Recover LP2.5 is proposed in most severe patients.
Methods: Retrospective single center registry from January 2007 to October 2010. All survivors of out-of-hospital cardiac arrest with patent or predictive factors for the occurrence of post-resuscitation shock assisted by either IMPELLA or intra aortic balloon pump (IABP) device immediately after the coronary angiogram were included.
Results: 78 post-cardiac arrest patients were assisted by one of the devices (35 by IMPELLA and 43 by IABP). Median “”no flow”" and median “”low flow”" were similar at admission
as were hemodynamic parameters. The feasibility of IMPELLA implantation was good (97%). At 28 days, the survival rate without sequellae was 23.0% in the IMPELLA and 29.5% in the IABP group (p = 0.61). Vascular complications were observed equally in both groups (3 vs 2, p = 0.9). Serious bleeding complications occurred in 26% of IMPELLA patients vs 9% of IABP patients (p = 0.06).
Conclusion: Early LV assistance by the IMPELLA LP2.5 is feasible in patients with post-resuscitation shock. The rate of complications did not differ substantially in the two groups, except for a trend Kinase Inhibitor Library toward a higher rate of bleeding events with IMPELLA. These encouraging findings must be confirmed in a larger clinical study. (C) 2012 Elsevier Ireland Ltd. All rights reserved.”
“Purpose: To compare the long-term selleck chemicals llc anatomical and visual outcomes of patients with idiopathic epiretinal membrane (ERM) removed by vitrectomy and membrane peeling with or without the use of intravitreal injection of triamcinolone
acetonide (IVTA).
Methods: A retrospective chart review was performed. Subjects who underwent vitrectomy and who were followed over 12 months were included. The study included two groups of patients. In group 1 (71 eyes), the patients underwent vitrectomy and membrane peeling without the use of IVTA. In group 2 (27 eyes), 2 mg of IVTA was given at the end of the surgery. The main outcome measures were best-corrected visual acuity (BCVA), central foveal thickness (CFT) determined by optical coherence tomography (OCT), the number of cataract surgeries, and the use of anti-glaucomatous drugs during the follow-up period.
Results: This study included 98 eyes with ERM from 98 patients. There was no significant difference between the two groups with respect to age, gender, pre- and postoperative lens status, BCVA, CFT, or length of the follow-up period. The mean age for all of the patients was 62.45 +/- 10.